Literature DB >> 11338880

Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma.

J Nemunaitis1, T Fong, P Shabe, D Martineau, D Ando.   

Abstract

Melanoma is an immunoresponsive malignancy. Interleukin-10 (IL-10) is a potent regulator of immunosuppression. The purpose of this research was to define the relationship of serum IL-10 to survival in patients with metastatic melanoma. Forty-one melanoma patients and 50 normal volunteers were analyzed. The median IL-10 level as determined by enzyme-linked immunosorbent assay (ELISA) in melanoma patients was 8.75 pg/ml compared to < 3.0 pg/ml in normal volunteers (p = 0.0001). Survival of melanoma patients with an IL-10 level above 10.0 pg/ml was 365 days compared to 557 days in patients with IL-10 levels less than 10.0 pg/ml (p = 0.0259, Wilcoxon). Elevated IL-10 levels were correlated with poor survival.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11338880     DOI： 10.1081/cnv-100102550

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  30 in total

1.  IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.

Authors:  Zhaojun Sun; Julien Fourcade; Ornella Pagliano; Joe-Marc Chauvin; Cindy Sander; John M Kirkwood; Hassane M Zarour
Journal:  Cancer Res       Date:  2015-02-26       Impact factor: 12.701

2.  Strength training reduces circulating interleukin-6 but not brain-derived neurotrophic factor in community-dwelling elderly individuals.

Authors:  Louis Nuvagah Forti; Rose Njemini; Ingo Beyer; Elke Eelbode; Romain Meeusen; Tony Mets; Ivan Bautmans
Journal:  Age (Dordr)       Date:  2014-08-16

3.  [Serum markers for melanoma].

Authors:  S Ugurel
Journal:  Hautarzt       Date:  2005-02       Impact factor: 0.751

Review 4.  Targeting IL-10 Family Cytokines for the Treatment of Human Diseases.

Authors:  Xiaoting Wang; Kit Wong; Wenjun Ouyang; Sascha Rutz
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-02-01       Impact factor: 10.005

Review 5.  Circulating serologic and molecular biomarkers in malignant melanoma.

Authors:  Shanique R Palmer; Lori A Erickson; Ilia Ichetovkin; Daniel J Knauer; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

6.  Ascites IL-10 Promotes Ovarian Cancer Cell Migration.

Authors:  Denis Lane; Isabelle Matte; Perrine Garde-Granger; Paul Bessette; Alain Piché
Journal:  Cancer Microenviron       Date:  2018-07-23

7.  Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions.

Authors:  Gianni Gerlini; Adrian Tun-Kyi; Christa Dudli; Günter Burg; Nicola Pimpinelli; Frank O Nestle
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

8.  Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.

Authors:  Christopher E Touloukian; Wolfgang W Leitner; Rhonda E Schnur; Paul F Robbins; Yong Li; Scott Southwood; Alessandro Sette; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

9.  Celecoxib and fish oil: a combination strategy for decreased inflammatory mediators in early stages of experimental mammary cancer.

Authors:  Anjana Kumari Negi; Archana Bhatnagar; Navneet Agnihotri
Journal:  Inflammopharmacology       Date:  2016-01-09       Impact factor: 4.473

10.  Role of interleukin-10 in the regulation of tumorigenicity of a T cell lymphoma.

Authors:  Mona R Hassuneh; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Leuk Lymphoma       Date:  2013-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.